← Back to Search

Antifibrinolytic Agent

Tranexamic Acid (TXA) for Hip Fracture

Phase 4

Waitlist Available

Led By Gregory M Georgiadis, MD

Research Sponsored by Gregory Georgiadis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 72 hours

Awards & highlights

Study Summary

This trial will test if giving Tranexamic Acid to patients before, during, and after surgery will decrease blood loss and the need for transfusions afterwards.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 72 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~72 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

proportion of patients requiring packed Red Blood Cell transfusion

Secondary outcome measures

intraoperative blood loss

postoperative anemia

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Experimental ArmExperimental Treatment1 Intervention

Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.

Group II: Control ArmPlacebo Group1 Intervention

Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tranexamic acid

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Gregory GeorgiadisLead Sponsor

Gregory M Georgiadis MDLead Sponsor

Gregory M Georgiadis, MDPrincipal InvestigatorProMedica Toledo Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please elucidate on any further research that has been conducted regarding Tranexamic Acid (TXA)?

"The current total of active clinical trials for Tranexamic Acid (TXA) is 61, with 26 being in Phase 3. These studies are scattered around 185 sites worldwide while the bulk of them can be found in Kansas City, Kansas."

Answered by AI

What risks are associated with Tranexamic Acid (TXA) usage?

"Tranexamic Acid (TXA) is an approved therapy, so our team has assigned it a score of 3 on the safety scale."

Answered by AI

What is the common purpose of Tranexamic Acid (TXA) ingestion?

"TXA, commonly used to suppress hyperfibrinolysis, is also suitable for the treatment of hemophilia and other bleeding issues such as those following a tooth extraction."

Answered by AI

Are there still opportunities to join this research endeavor?

"Per the details posted on clinicaltrials.gov, this research project is actively recruiting participants. It was initially advertised at the end of August 2017 and last revised during September 2021."

Answered by AI

How many volunteers are engaged in this research project?

"Affirmative. The clinical trial has been advertised on clincialtrials.gov since August 30th 2017 and was most recently updated in September 2021, indicating that it is still recruiting for 200 participants across 1 site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Gregory M Georgiadis MD 2017. "Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03063892.